New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 5, 2014
08:17 EDTDARADara signs agreement with WellCare for Soltamox formulary status
DARA BioSciences announced that the company signed a Medicare Part D Prescription Drug Program Reimbursement Agreement with Comprehensive Health Management, providing formulary status for the WellCare Group of companies for Soltamox oral solution. DARA holds exclusive U.S. marketing rights to Soltamox.
News For DARA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 19, 2015
14:39 EDTDARADara BioSciences granted additional 180-day period to regain NASDAQ compliance
On May 19, DARA BioSciences received a notification letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the NASDAQ Listing Qualifications Staff has granted the company's request for an additional 180-day period in which to regain compliance with the minimum $1.00 bid price per share requirement. The NASDAQ Listing Qualifications Staff's determination to grant the additional 180 day compliance period was based on the Company meeting the continued listing requirement for market value of publicly held shares and all other applicable requirements for initial listing on the NASDAQ Capital Market, with the exception of the bid price requirement, and the Company's written notice of its intention to cure the deficiency during the additional 180-day compliance period by effecting a reverse stock split, if necessary.
May 13, 2015
16:19 EDTDARADara BioSciences reports Q1 EPS (16c), consensus (13c)
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use